IL-23IL-23

Back to Disease

January 2026

Journal Club: Guselkumab Binds To CD64+ IL-23–Producing Myeloid Cells to Neutralize IL-23 Signals

December 2025

Medication Review: Describe the Dual Mechanism of Action of Guselkumab

January 2026

FAQ: What Is the Correlation of CD64 and IL-23 Expression in Inflamed Joint, Skin, and Gut Tissue?

October 2025

Medication Review: What Is the Evidence For Guselkumab Efficacy In Inhibiting The Progression of Structural Damage?

December 2025

FAQ: What is the Normal Role of CD64 in Innate and Adaptive Immunity?

December 2025

FAQ: Why is the mvdH-S Score Used Most Often in PsA Trials?

December 2025

FAQ: How Does The Design of APEX Differ From DISCOVER-2 To Enrich For Structural Damage?

March 2025

Long-Term Guselkumab Safety in Psoriasis & PsA (Phase II/III Analysis)

October 2025

What Is the Clinical Significance of Structural Damage in PsA?

May 2025

What is the Real World Evidence of Guselkumab in PsA

sectionimg

dotsimg

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play